Alexion Pharmaceuticals Inc.

Alexion Pharmaceuticals is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the development and commercialization of therapies. The company is engaged in complement inhibition and has developed and commercialized two complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria, as well as the complement inhibitor to treat atypical hemolytic uremic syndrome and anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. In addition, the company has two enzyme replacement therapies for patients with metabolic disorders, hypophosphatasia and lysosomal acid lipase deficiency.
  • TickerALXN
  • ISINUS0153511094
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

Laura Chico

ALXN_20190716

Wedbush Research

Wedbush Morning Call - Jul 16 2019 6:50AM

Laura Chico

Ahead of 2Q19 Biotech Reporting - Thoughts on Commercial Names

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Laura Chico

ALXN_20190716

Wedbush Research

Wedbush Morning Call - Jul 16 2019 6:50AM

Laura Chico

Ahead of 2Q19 Biotech Reporting - Thoughts on Commercial Names

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

ALEXION PHARMS.INCO. presents increased market risk and shows a lower rating of Slightly Negative

The independent financial analyst theScreener just requalified the risk of ALEXION PHARMS.INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives a new star(s) and now shows 2 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and can be qualified as risky. theScreener considers that these elements lead to an overall rating downgrade to Slightly Negative while the title remains exposed to strong pressure. As of the analysis date June 21, 2019, the closing price was USD 132.39 and its target price was estimated at...

MarketLine Department

MorphoSys AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's MorphoSys AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by MorphoSys AG since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlight...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • We are upgrading Health Care to an overweight. XLV is breaking topside a bullish base and reversing a 9-month RS downtrend. • Biotechs are leadership and are breaking out of bullish consolidation. XBI and IBB are constructive and making positive inflections. • Energy remains a leadership Sector with many bullish bases that are still unexploited. We have highlighted a number of them in today's Vital Signs.

Dave Nicoski

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength. For a trial to Vermilion Research visit our website at www.vermilioncap.com or contact our sales team at (952) 922-7500.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch